Mirati Therapeutics Inc. (MRTX)
Mirati Therapeutics Statistics
Share Statistics
Mirati Therapeutics has 70.15M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 70.15M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 38.91M |
| Failed to Deliver (FTD) Shares | 100 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -3.44 and the forward PE ratio is null. Mirati Therapeutics's PEG ratio is -0.2.
| PE Ratio | -3.44 |
| Forward PE | n/a |
| PS Ratio | 204.88 |
| Forward PS | n/a |
| PB Ratio | 2.56 |
| P/FCF Ratio | -4.43 |
| PEG Ratio | -0.2 |
Enterprise Valuation
Mirati Therapeutics has an Enterprise Value (EV) of 2.36B.
| EV / Sales | 190.1 |
| EV / EBITDA | -3.12 |
| EV / EBIT | -4.14 |
| EV / FCF | -4.11 |
Financial Position
The company has a current ratio of 6.96, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.96 |
| Quick Ratio | 6.94 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.07 |
| Debt / FCF | -0.09 |
| Interest Coverage | 42.3 |
Financial Efficiency
Return on Equity is -74.35% and Return on Invested Capital is -75.68%.
| Return on Equity | -74.35% |
| Return on Assets | -61.6% |
| Return on Invested Capital | -75.68% |
| Revenue Per Employee | $21.19K |
| Profits Per Employee | $-1.26M |
| Employee Count | 587 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.2 |
Taxes
| Income Tax | 508K |
| Effective Tax Rate | -0.07% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 0.77, so Mirati Therapeutics's price volatility has been higher than the market average.
| Beta | 0.77 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 57.75 |
| 200-Day Moving Average | 45.58 |
| Relative Strength Index (RSI) | 56.14 |
| Average Volume (20 Days) | 1.78M |
Income Statement
In the last 12 months, Mirati Therapeutics had revenue of 12.44M and earned -740.87M in profits. Earnings per share was -13.18.
| Revenue | 12.44M |
| Gross Profit | 11.84M |
| Operating Income | -759.59M |
| Net Income | -740.87M |
| EBITDA | -756.66M |
| EBIT | -758.32M |
| Earnings Per Share (EPS) | -13.18 |
Balance Sheet
The company has 235.26M in cash and 51.51M in debt, giving a net cash position of 183.75M.
| Cash & Cash Equivalents | 235.26M |
| Total Debt | 51.51M |
| Net Cash | 183.75M |
| Retained Earnings | -2.45B |
| Total Assets | 1.13B |
| Working Capital | 898.7M |
Cash Flow
In the last 12 months, operating cash flow was -570.57M and capital expenditures -4.85M, giving a free cash flow of -575.42M.
| Operating Cash Flow | -570.57M |
| Capital Expenditures | -4.85M |
| Free Cash Flow | -575.42M |
| FCF Per Share | -10.23 |
Margins
Gross margin is 95.18%, with operating and profit margins of -6107.98% and -5957.44%.
| Gross Margin | 95.18% |
| Operating Margin | -6107.98% |
| Pretax Margin | -5953.35% |
| Profit Margin | -5957.44% |
| EBITDA Margin | -6084.43% |
| EBIT Margin | -6107.98% |
| FCF Margin | -4627.06% |
Dividends & Yields
MRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -29.08% |
| FCF Yield | -22.58% |
Analyst Forecast
Currently there are no analyst rating for MRTX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 3, 2013. It was a backward split with a ratio of 1:50.
| Last Split Date | Jul 3, 2013 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | 8.55 |
| Piotroski F-Score | 3 |